Logo Logo
Help
Contact
Switch Language to German

Thelen, Martin; Wennhold, Kerstin; Lehmann, Jonas; Garcia-Marquez, Maria; Klein, Sebastian; Kochen, Elena; Lohneis, Philipp; Lechner, Axel; Wagener-Ryczek, Svenja; Plum, Patrick Sven; Velazquez Camacho, Oscar; Pfister, David; Doerr, Fabian; Heldwein, Matthias; Hekmat, Khosro; Beutner, Dirk; Klussmann, Jens Peter; Thangarajah, Fabinshy; Ratiu, Dominik; Malter, Wolfram; Merkelbach-Bruse, Sabine; Bruns, Christiane Josephine; Quaas, Alexander; Bergwelt-Baildon, Michael von and Schloesser, Hans A. (2021): Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. In: Npj Precision Oncology, Vol. 5, No. 1, 52

Full text not available from 'Open Access LMU'.

Abstract

The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets and also expression of immune-regulatory molecules on tumor-infiltrating lymphocytes showed site-specific variation. Multiparametric analyses of these data identified similarities of renal and liver or lung with head and neck cancer. Co-expression of immune-inhibitory ligands on tumor cells was most frequent in colorectal, lung and ovarian cancer. Genes related to antigen presentation were frequently dysregulated in liver and lung cancer. Expression of co-inhibitory molecules on tumor-infiltrating T cells accumulated in advanced stages while T-cell abundance was related to enhanced expression of genes related to antigen presentation. Our results promote evaluation of cancer-specific or even personalized immunotherapeutic combinations to overcome primary or secondary resistance as major limitation of immune-checkpoint inhibition.

Actions (login required)

View Item View Item